Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Brexu-cel
Brexucabtagene autoleucel
Bruton tyrosine kinase inhibitor
CAR T cell therapy
KTE-X19
MAIC
Mantle cell lymphoma
Matching-adjusted indirect comparison
Non-Hodgkin lymphoma
Pirtobrutinib
Journal
Advances in therapy
ISSN: 1865-8652
Titre abrégé: Adv Ther
Pays: United States
ID NLM: 8611864
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
received:
22
12
2023
accepted:
12
02
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
aheadofprint
Résumé
Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. Newer treatments such as brexucabtagene autoleucel (brexu-cel, chimeric antigen receptor T cell therapy) and pirtobrutinib (non-covalent BTKi) show promise in improving outcomes. Without direct comparative evidence, an unanchored matching-adjusted indirect comparison was conducted to estimate the relative treatment effects of brexu-cel and pirtobrutinib for post-cBTKi R/R MCL. Using logistic propensity score models, individual patient-level data from ZUMA-2 brexu-cel-infused population (N = 68) were weighted to match pre-specified clinically relevant prognostic factors based on study-level data from the BRUIN cBTKi pre-treated cohort (N = 90). The base-case model incorporated the five most pertinent factors reported in ≥ 50% of both trial populations: morphology, MCL International Prognostic Index, number of prior lines of therapy, disease stage, and prior autologous stem cell transplant. A sensitivity analysis additionally incorporated TP53 mutation and Ki-67 proliferation. Relative treatment effects were expressed as odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CIs). In the base-case model, brexu-cel was associated with higher rates of objective response (OR 10.39 [95% CI 2.81-38.46]) and complete response (OR 10.11 [95% CI 4.26-24.00]), and improved progression-free survival (HR 0.44 [95% CI 0.25-0.75]), compared to pirtobrutinib. Overall survival and duration of response favored brexu-cel over pirtobrutinib but the differences crossed the bounds for statistical significance. Findings were consistent across the adjusted and unadjusted analyses. Findings suggest that brexu-cel may offer clinically and statistically significant benefits regarding objective response, complete response, and progression-free survival compared to pirtobrutinib among patients with R/R MCL after prior cBTKi therapy. Given the short follow-up and high degree of censoring in BRUIN, an analysis incorporating updated BRUIN data may provide more definitive overall survival results.
Identifiants
pubmed: 38494543
doi: 10.1007/s12325-024-02822-z
pii: 10.1007/s12325-024-02822-z
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
American Cancer Society. Types of B-cell lymphoma 2019 [updated January 29, 2019]. https://www.cancer.org/cancer/types/non-hodgkin-lymphoma/about/b-cell-lymphoma.html . Accessed 2023 Aug 27.
Inwards DJ, Witzig TE. Initial therapy of mantle cell lymphoma. Ther Adv Hematol. 2011;2(6):381–92.
doi: 10.1177/2040620711412418
pubmed: 23556104
pmcid: 3573424
Owen C, Berinstein NL, Christofides A, Sehn LH. Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. Curr Oncol. 2019;26(2):e233–40.
doi: 10.3747/co.26.4345
pubmed: 31043832
pmcid: 6476444
Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.
doi: 10.1186/s13045-017-0537-5
pubmed: 29096668
pmcid: 5668956
McKay P, Leach M, Jackson B, Robinson S, Rule S. Guideline for the management of mantle cell lymphoma. Br J Haematol. 2018;182(1):46–62.
doi: 10.1111/bjh.15283
pubmed: 29767454
Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):e68–71.
doi: 10.3324/haematol.2018.198812
pubmed: 30190341
pmcid: 6355471
McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684–8.
doi: 10.1111/bjh.16416
pubmed: 32011729
Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.
doi: 10.1111/bjh.15567
pubmed: 30175400
Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–63.
doi: 10.1182/blood-2015-10-673145
pubmed: 26764355
Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022;202(4):749–59.
doi: 10.1111/bjh.18519
pubmed: 36257914
Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.
doi: 10.1056/NEJMoa1914347
pubmed: 32242358
pmcid: 7731441
Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023:JCO2102370.
US Food and Drug Administration. TECARTUS (brexucabtagene autoleucel) prescribing information 2021 [updated October 2021]. https://www.fda.gov/media/140409/download?attachment . Accessed 2023 Aug 27.
European Medicines Agency. Tecartus: EPAR—Product information 2023 [updated November 28, 2023]. https://www.ema.europa.eu/en/medicines/human/EPAR/tecartus . Accessed 2023 Aug 27.
Wang ML, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. J Clin Oncol. 2023:101200JCO2300562.
US Food and Drug Administration. JAYPIRCA (pirtobrutinib) prescribing information 2023 [updated January 2023]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216059Orig1s000Corrected_lbl.pdf . Accessed 2023 Aug 27.
European Medicines Agency. Jaypirca : EPAR—Public assessment report 2023 [updated November 20, 2023; cited 2023 December 4]. https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca .
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for Initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–67.
doi: 10.1200/JCO.2013.54.8800
pubmed: 25113753
pmcid: 4979083
Wang ML, Shah NN, Jurczak W, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood. 2022;140(Supplement 1):9368–72.
doi: 10.1182/blood-2022-159425
Shah NN, Jurczak W, Zinzani PL, et al. Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): updated results and subgroup analysis from the phase 1/2 BRUIN study with 2 years of survival follow-up. In: Presented at American Society of clinical oncology 59th annual meeting; Chicago, IL; June 2–6, 2023. 2023.
Cohen JB, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. Blood. 2023;142:981.
doi: 10.1182/blood-2023-181627
Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.
doi: 10.1186/1471-2288-12-9
pubmed: 22297116
pmcid: 3313891
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Dec Mak. 2018;38(2):200–11.
doi: 10.1177/0272989X17725740
Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81(3):515–26.
doi: 10.1093/biomet/81.3.515
Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals for survival models. Biometrika. 1990;77(1):147–60.
doi: 10.1093/biomet/77.1.147
Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016.
Dreyling M, Shah B, Wu JJ, et al. SA29 efficacy outcomes following treatment with Bruton tyrosine kinase inhibitors (BTKI) for relapsed/refractory mantle cell lymphoma (R/R MCL): a literature-based meta-analysis. Value Health. 2022;25(7):S609–10.
doi: 10.1016/j.jval.2022.04.1695
Dreyling M, Shah B, Wu J, et al. MCL-373 unmet need in relapsed/refractory (RR) mantle cell lymphoma (MCL) post-Bruton tyrosine kinase inhibitor (BTKi): systematic literature review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2023;23:S461–2.
doi: 10.1016/S2152-2650(23)01377-0
Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594–606.
doi: 10.1200/JCO.22.01797
pubmed: 36753699
Kambhampati S, Ahmed N, Hamadani M, et al. Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): a CIBMTR subgroup analysis of high-risk characteristics. Blood. 2023;142:107.
doi: 10.1182/blood-2023-179269
Herbaux C, Bret C, Di Blasi R, et al. Kte-X19 in relapsed or refractory mantle-cell lymphoma, a “real-life” study from the Descar-T Registry and Lysa Group. Blood. 2021;138:743.
doi: 10.1182/blood-2021-148626
Hess G, Vucinic V, Rejeski K, et al. Real world results of brexucabtagene autoleucel for patients with relapsed/refractory mantle cell lymphoma-first German/Swiss analysis. Blood. 2023;142:4394.
doi: 10.1182/blood-2023-182415
O’Reilly MA, Sanderson R, Wilson W, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world outcomes In the United Kingdom. Blood. 2022;140(Suppl 1):7519–21.
doi: 10.1182/blood-2022-165031
Hess G, Dreyling M, Oberic L, et al. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leukemia Lymphoma. 2024;65(1):14–25.
Huang Z, Chavda VP, Bezbaruah R, Dhamne H, Yang D-H, Zhao H-B. CAR T-cell therapy for the management of mantle cell lymphoma. Mol Cancer. 2023;22(1):1–19.
doi: 10.1186/s12943-023-01755-5
Cohen JB, Shah NN, Jurczak W, et al. 981 Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN Study. American Society of Hematology Annual Meeting; 2023.
Mato AR, Nabhan C, Thompson MC, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103(5):874.
doi: 10.3324/haematol.2017.182907
pubmed: 29419429
pmcid: 5927982